Accessibility Menu
 
Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

(NASDAQ) LXRX

Current Price$1.67
Market Cap$716.02M
Since IPO (2000)-99%
5 Year-67%
1 Year+139%
1 Month+2%

Lexicon Pharmaceuticals Financials at a Glance

Market Cap

$716.02M

Revenue (TTM)

$49.80M

Net Income (TTM)

$50.34M

EPS (TTM)

$-0.14

P/E Ratio

-12.18

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$1.67

Volume

762,658.136

Open

$1.69

Previous Close

$1.69

Daily Range

$1.66 - $1.72

52-Week Range

$0.51 - $1.95

LXRX: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexicon Pharmaceuticals

Industry

Pharmaceuticals

Employees

81

CEO

Michael Exton, PhD

Headquarters

The Woodlands, TX 77381, US

LXRX Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-98%

Net Income Margin

-1%

Return on Equity

-40%

Return on Capital

-30%

Return on Assets

-27%

Earnings Yield

-8.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$716.02M

Shares Outstanding

423.68M

Volume

762.66K

Avg. Volume

2.70M

Financials (TTM)

Gross Profit

$49.53M

Operating Income

$48.91M

EBITDA

$48.29M

Operating Cash Flow

$67.85M

Capital Expenditure

$0.00

Free Cash Flow

$67.85M

Cash & ST Invst.

$96.23M

Total Debt

$62.24M

Lexicon Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$5.49M

-79.3%

Gross Profit

$5.17M

+733.2%

Gross Margin

94.19%

N/A

Market Cap

$716.02M

N/A

Market Cap/Employee

$6.95M

N/A

Employees

103

N/A

Net Income

$15.53M

+54.0%

EBITDA

$14.66M

+27.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$33.99M

-73.8%

Accounts Receivable

$2.38M

-31.4%

Inventory

$281.00K

+21.6%

Long Term Debt

$56.00M

-47.8%

Short Term Debt

$6.24M

+430.8%

Return on Assets

-27.21%

N/A

Return on Invested Capital

-29.80%

N/A

Free Cash Flow

$17.23M

+21.5%

Operating Cash Flow

$17.23M

+19.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCGNOcugen, Inc.
$1.68-1.18%
FDMT4D Molecular Therapeutics, Inc.
$9.51+0.58%
ADCTADC Therapeutics S.A.
$3.75-0.40%
RAPTRAPT Therapeutics, Inc.
$58.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$60.92-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.27-0.00%
ERASErasca
$9.95-0.48%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$53.94+0.03%

Questions About LXRX

What is the current price of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals is trading at $1.67 per share.

What is the 52-week range for Lexicon Pharmaceuticals?

Over the past 52 weeks, Lexicon Pharmaceuticals has traded between $0.51 and $1.95.

How much debt does Lexicon Pharmaceuticals have?

As of the most recent reporting period, Lexicon Pharmaceuticals reported total debt of $62.24M.

How much cash does Lexicon Pharmaceuticals have on hand?

Lexicon Pharmaceuticals reported $34.33M in cash and cash equivalents in its most recent financial results.

What is Lexicon Pharmaceuticals’s dividend yield?

Lexicon Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.